Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: Ten-Year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853 - A study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group

被引:482
|
作者
Bijker, Nina
Meijnen, Philip
Peterse, Johannes L.
Bogaerts, Jan
Van Hoorebeeck, Irene
Julien, Jean-Pierre
Gennaro, Massimiliano
Rouanet, Philippe
Avril, Antoine
Fentiman, Ian S.
Bartelink, Harry
Rutgers, Emiel J. Th.
机构
[1] Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Dept Radiat Oncol, NL-1066 CX Amsterdam, Netherlands
[2] Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Dept Surg, NL-1066 CX Amsterdam, Netherlands
[3] Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Dept Pathol, NL-1066 CX Amsterdam, Netherlands
[4] European Org Res Treatment Canc, Ctr Data, Brussels, Belgium
[5] Ctr Henri Becquerel, Dept Surg, F-76038 Rouen, France
[6] CRLC Val DAurelle, Dept Surg, Montpellier, France
[7] Inst Bergonie, Dept Surg, Bordeaux, France
[8] Ist Nazl Tumori, Dept Surg, I-20133 Milan, Italy
[9] Guys Hosp, Dept Acad Oncol, London SE1 9RT, England
关键词
D O I
10.1200/JCO.2006.06.1366
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose The European Organisation for Research and Treatment of Cancer conducted a randomized trial investigating the role of radiotherapy (RT) after local excision (LE) of ductal carcinoma-in-situ (DCIS) of the breast. We analyzed the efficacy of RT with 10 years follow-up on both the overall risk of local recurrence (LR) and related to clinical, histologic, and treatment factors. Patients and Methods After complete LE, women with DCIS were randomly assigned to no further treatment or RT (50 Gy). One thousand ten women with mostly (71%) mammographically detected DCIS were included. The median follow-up was 10.5 years. Results The 10-year LR-free rate was 74% in the group treated with LE alone compared with 85% in the women treated by LE plus RT (log-rank P <.0001, hazard ratio [HR] = 0.53). The risk of DCIS and invasive LR was reduced by 48% (P =.0011) and 42% (P =.0065) respectively. Both groups had similar low risks of metastases and death. At multivariate analysis, factors significantly associated with an increased LR risk were young age (<= 40 years; HB = 1.89), symptomatic detection (HR = 1.55), intermediately or poorly differentiated DCIS (as opposed to well-differentiated DCIS; HR = 1.85 and HR = 1.61 respectively), cribriform or solid growth pattern (as opposed to clinging/micropapillary subtypes; HR = 2.39 and HR = 2.25 respectively), doubtful margins (HR = 1.84), and treatment by LE alone (HR = 1.82). The effect of RT was homogeneous across all assessed risk factors. Conclusion With long-term follow-up, RT after LE for DCIS continued to reduce the risk of LR, with a 47% reduction at 10 years. All patient subgroups benefited from RT.
引用
收藏
页码:3381 / 3387
页数:7
相关论文
共 50 条
  • [31] THE FEASIBILITY OF HIGH-DOSE MULTIPLE DAILY FRACTIONATION AND ITS COMBINATION WITH ANOXIC CELL SENSITIZERS IN THE TREATMENT OF HEAD AND NECK-CANCER - A PILOT-STUDY OF THE RADIOTHERAPY GROUP OF THE EORTC (EUROPEAN-ORGANISATION-FOR-RESEARCH-ON-TREATMENT-OF-CANCER)
    VANDENBOGAERT, W
    VANDERSCHUEREN, E
    HORIOT, JC
    CHAPLAIN, G
    ARCANGELI, G
    GONZALEZ, D
    SVOBODA, V
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1982, 8 (10): : 1649 - 1655
  • [32] Radical Nephrectomy with and without Lymph-Node Dissection: Final Results of European Organization for Research and Treatment of Cancer (EORTC) Randomized Phase 3 Trial 30881
    Blom, Jan H. M.
    van Poppel, Hein
    Marechal, Jean M.
    Jacqmin, Didier
    Schroder, Fritz H.
    de Prijck, Linda
    Sylvester, Richard
    EUROPEAN UROLOGY, 2009, 55 (01) : 28 - 34
  • [33] Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II:: An European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874)
    Reed, N. S.
    Mangioni, C.
    Malmstrom, H.
    Scarfone, G.
    Poveda, A.
    Pecorelli, S.
    Tateo, S.
    Franchi, M.
    Jobsen, J. J.
    Coens, C.
    Teodorovic, I.
    Vergote, I.
    Vermorken, J. B.
    EUROPEAN JOURNAL OF CANCER, 2008, 44 (06) : 808 - 818
  • [34] Sagopilone (ZK-EPO, ZK 219477) for recurrent glioblastoma. A phase II multicenter trial by the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor Group
    Stupp, R.
    Tosoni, A.
    Bromberg, J. E. C.
    Hau, P.
    Campone, M.
    Gijtenbeek, J.
    Frenay, M.
    Breimer, L.
    Wiesinger, H.
    Allgeier, A.
    van den Bent, M. J.
    Bogdahn, U.
    van der Graaf, W.
    Yun, H. J.
    Gorlia, T.
    Lacombe, D.
    Brandes, A. A.
    ANNALS OF ONCOLOGY, 2011, 22 (09) : 2144 - 2149
  • [35] High local recurrence risk after breast-conserving therapy in node-negative premenopausal breast cancer patients is greatly reduced by one course of perioperative chemotherapy: A European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group study
    Elkhuizen, PHM
    van Slooten, HJ
    Clahsen, PC
    Hermans, J
    van de Velde, CJH
    van den Broek, LCJM
    van de Vijver, MJ
    JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (05) : 1075 - 1083
  • [36] Hypofractionated radiotherapy with simultaneous tumor bed boost (Hi-RISE) in breast cancer patients receiving upfront breast-conserving surgery: study protocol for a phase III randomized controlled trial
    Jin, Kairui
    Luo, Jurui
    Yu, Xiaoli
    Guo, Xiaomao
    RADIATION ONCOLOGY, 2024, 19 (01)
  • [37] Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: An intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada
    van Meerbeeck, JP
    Gaafar, R
    Manegold, C
    Van Klaveren, RJ
    Van Marck, EA
    Vincent, M
    Legrand, C
    Bottomley, A
    Debruyne, C
    Giaccone, G
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (28) : 6881 - 6889
  • [38] Endocrine therapy with or without whole breast irradiation in low-risk breast cancer patients after breast-conserving surgery: 10-year results of the Austrian Breast and Colorectal Cancer Study Group 8A trial
    Fastner, Gerd
    Sedlmayer, Felix
    Widder, Joachim
    Metz, Martina
    Geinitz, Hans
    Kapp, Karin
    Fesl, Christian
    Soelkner, Lidija
    Greil, Richard
    Jakesz, Raimund
    Kwasny, Werner
    Heck, Dietmar
    Bjelic-Radisic, Vesna
    Balic, Marija
    Stoeger, Herbert
    Wieder, Ursula
    Zwrtek, Ronald
    Semmler, Dagmar
    Horvath, Wilfried
    Melbinger-Zeinitzer, Elisabeth
    Wiesholzer, Martin
    Wette, Viktor
    Gnant, Michael
    EUROPEAN JOURNAL OF CANCER, 2020, 127 : 12 - 20
  • [39] Re: Radical Nephrectomy with and without Lymph-Node Dissection: Final Results of European organization for Research and Treatment of Cancer (EORTC) Randomized Phase 3 Trial 30881
    Ljungberg, Borje
    EUROPEAN UROLOGY, 2009, 55 (06) : 1486 - 1487
  • [40] Treatment of brain metastases of small-cell lung cancer: Comparing teniposide and teniposide with whole-brain radiotherapy - A phase III study of the European Organization for the Research and Treatment of Cancer Lung Cancer Cooperative Group
    Postmus, PE
    Haaxma-Reiche, H
    Smit, EF
    Groen, HJM
    Karnicka, H
    Lewinski, T
    van Meerbeeck, J
    Clerico, M
    Gregor, A
    Curran, D
    Sahmoud, T
    Kirkpatrick, A
    Giaccone, G
    JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (19) : 3400 - 3408